Dilip Shanghvi

India's billionaire club shrinks to 120, Gautam Adani tops rich list

In comparison, Ambani, who topped the list last year, has seen a 2.5 per cent decline in his family's net worth to $101.75 billion from $104.4 billion a year ago

Ahead of rights issue, charts hint steady gains for Suzlon; 200-DMA is key

There is a bullish formation of a "Higher High, Higher Low" pattern on the daily chart, and only if the stock breaks the 200-DMA the trend could turn negative.

Shanghvi says will participate in Suzlon Energy's Rs 1,200-cr rights issue

The rights issue will open on October 11, closing on October 20

Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

From DRL to Glenmark, pharma companies see steady revenue growth in Russia

Strong sales in Q4 during war aided by 'stocking up of inventory'

Sun Pharma eyes high single digit top line growth in FY23: Dilip Shanghvi

Drug major Sun Pharma on Monday said it expects high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal. "We expect high single-digit top-line growth for FY23. All our businesses are positioned for growth. Ramp up in our global speciality business is expected to continue," Sun Pharma Managing Director Dilip Shanghvi said in an analyst call. He noted that markets across the globe were now in the process of normalising. "R&D investments are expected to be between 7-8 per cent of sales next year," Shanghvi noted. On its Halol-based manufacturing plant, he stated that the company will be filing its response to the FDA on the corrective actions to be undertaken to address the observations within the stipulated time. Earlier this month, the US health regulator had issued a ...

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

SPARC raises over Rs 1,110 cr; issues warrants to Dilip Shanghvi, others

Sun Pharma Advanced Research Company on Thursday said it has raised over Rs 1,112 crore by way of issuing warrants to the company's promoter Dilip Shanghvi and other entities

Sun Pharma, 7 executives settle dispute with Sebi; pay Rs 2.92 cr

Two whistle blowers had alleged that Sun Pharma and its subsidiary Sun Pharmaceutical Laboratories diverted funds through its sole distributor in India Aditya Medisales

Sun Pharma's Q2 net profit rises 70% on one-time tax credit

Revenues remain flat, sequential improvement in India and US revenues

Will continue to focus on growing business faster than market: Sun Pharma

The company's strategy of developing the Specialty business as an additional growth engine has started delivering, with a gradual ramp up in specialty revenues, Shanghvi said

Corona warriors for markets: Ambani, Adani stocks rise most since lockdown

The Bajaj group is the only one on the list of 12 conglomerates to be down - 1 per cent - since the lockdown came into effect, thanks to the hammering of stocks of non-banking financial companies.

Dilip Shanghvi staring at huge loss as Suzlon Energy heads to bankruptcy

Dilip Shanghvi, the Sun Pharma promoter has 23% in renewable power firm that has failed to get debt recast plan

Sun Pharma signs global licensing pact with CSIR-IICT for patents

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications

Dilip Shanghvi takes 99% pay cut despite Sun Pharma's 27% earnings growth

Shanghvi, one of the lowest-paid CEOs in India's pharmaceutical sector, drew a salary of Rs 1 during 2018-19

Sun Pharma aims to clock 'low-to-mid teens' growth in revenues in FY20

Drug major Sun Pharmaceutical Industries is gradually ramping up its speciality business across global markets as it aims to clock "low-to-mid teens" growth in consolidated revenues in the current fiscal. Addressing shareholders in the company's annual report for 2018-19, Sun Pharma Managing Director Dilip Shanghvi said the company is focused at growing each of its business verticals faster than the market in which it operates. "Our consistent focus is on growing each of our businesses faster than the market in which they operate. Our global specialty initiatives will supplement this objective as an additional growth engine," Shanghvi said. The company is targeting key ailments like psoriasis to gradually ramp up its global specialty business, he said adding that Sun Pharma would continue to invest in branding and promotion of its various specialty products. Besides, R&D investments for funding clinical trials of some of the specialty products are also likely to continue in ...

What billionaire Shanghvi sees in debt-laden Suzlon that no one else does

Shanghvi proved a white knight for Suzlon in 2015 when he bought 23 percent stake for Rs 18 billion

Dilip Shanghvi's MJ Pharmaceuticals invested Rs 110 cr in realty projects

In one of these projects, MJ Pharma's share in profit or loss is 30%, while in the other four projects, it is 37.5%

Dilip Shanghvi, the man behind India's best stock, faces his biggest test

Shares of Sun Pharma have hit a wall after surging for 20 years

Will not just 'Make in India' but 'Innovate in India': Dilip Shanghvi

Talking about his business turn over, he said that US is the largest market for his company, adding almost 50% of the turnover is in US